Industry groups, along with many rare disease and patient advocacy groups, appear behind the acting commissioner getting the permanent position.
Supporters of Janet Woodcock’s bid to become commissioner of the US Food and Drug Administration are emerging, although one of the biggest is choosing to stay in the background.
Dozens of rare disease and other patient organizations have penned letters supporting Woodcock, who currently is the acting FDA commissioner....
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
